Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Researchers Discover Tumor Growth, Angiogenesis Inhibitor

By Drug Discovery Trends Editor | June 19, 2014

A previously unknown variant of an extensively studied protein has been found to inhibit the growth of tumors and slow the development of new blood vessels necessary for cancers to metastasize, according to Cleveland Clinic research published in Cell.
 
The creation of new blood vessels, or angiogenesis, is a vital part of cancer growth and metastasis. Blood vessels carry nutrients and oxygen, which tumors need to survive, expand, and migrate to other parts of the body. A family of proteins called vascular endothelial growth factors (VEGFs) are behind the process of angiogenesis, and one particular protein, VEGF-A, is the principal driver in the process.
 
However, a research team led by Paul Fox, Ph.D., of the Department of Cellular and Molecular Medicine in Cleveland Clinic’s Lerner Research Institute, has discovered that a variant of VEGF-A, one they call VEGF-Ax, actually decreases angiogenesis, cutting off the blood supply to tumors and inhibiting their development in animal models.
 
“This research is significant because it will open new avenues of angiogenesis and cancer research. It is important for patients as it could potentially lead to new diagnostic tools and improved treatments to reduce the spread of cancer.” Fox said. “It is truly remarkable that a small change in a protein sequence leads not just to a protein with a different function, but one with a function completely opposite to the original. In the context of cancer, the small extension changes a very ‘bad’ protein into a very ‘good’ one.”
 
VEGF-Ax is 22 amino acids longer that VEGF-A, and is formed when the ribosome—the cellular machinery that translates genes (actually messenger RNAs) into proteins—reads through its genetic stop sign in a process called programmed translational read through.
 
Date: June 19, 2014
Source: Cleveland Clinic

Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE